Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights

Overview

Journal Animals (Basel)

Date 2025 Feb 13

PMID 39943162

Authors

Michelle do Carmo Pereira Rocha

Diana Araujo

Fatima Carvalho

Nuno Vale

Josiane Morais Pazzini

Marcus Antonio Rossi Feliciano

Andrigo Barboza De Nardi

Irina Amorim

Affiliations

Soon will be listed here.

Abstract

Lymphoma accounts for 24% of all documented canine neoplasms and 85% of hematological malignancies, while multicentric lymphoma corresponds to 84% of all canine lymphomas. Canine lymphomas of B-cell origin account for 60% to 80% of lymphomas. Similar to humans, the histologic grade, architecture, as well as immunophenotype determination, are crucial. These lesions are the most prevalent spontaneous tumors in dogs and this species may be a valuable animal model for the study of human non-Hodgkin's lymphoma. Therefore, it is important to investigate and assess therapeutic responses and to seek predictive and prognostic factors in order to allow for the development of an individualized and more effective therapy that increases survival. This review aims to describe current knowledge on the diagnosis, treatment, and prognostic factors of canine multicentric lymphoma.

References

Wilson-Robles H, Bygott T, Kelly T, Miller T, Miller P, Matsushita M . Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res. 2022; 18(1):329. PMC: 9429572. DOI: 10.1186/s12917-022-03429-8. View

Zanelli M, Fragliasso V, Parente P, Bisagni A, Sanguedolce F, Zizzo M . Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art. Int J Mol Sci. 2024; 25(12). PMC: 11203507. DOI: 10.3390/ijms25126447. View

Yau P, Dhand N, Thomson P, Taylor R . Retrospective study on the occurrence of canine lymphoma and associated breed risks in a population of dogs in NSW (2001-2009). Aust Vet J. 2017; 95(5):149-155. DOI: 10.1111/avj.12576. View

Suter S, Chein M, von Messling V, Yip B, Cattaneo R, Vernau W . In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res. 2005; 11(4):1579-87. DOI: 10.1158/1078-0432.CCR-04-1944. View

Avery P, Burton J, Bromberek J, Seelig D, Elmslie R, Correa S . Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases. J Vet Intern Med. 2014; 28(2):538-46. PMC: 4857986. DOI: 10.1111/jvim.12304. View

Ubiali A, Conti L, DallAra P, De Maria R, Aresu L, Moretti P . Exploring the dynamics of Programmed Death-Ligand 1 in canine lymphoma: unraveling mRNA amount, surface membrane expression and plasmatic levels. Front Vet Sci. 2024; 11:1412227. PMC: 11310028. DOI: 10.3389/fvets.2024.1412227. View

Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri J, Luberto L . Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther. 2013; 24(8):728-38. PMC: 3746211. DOI: 10.1089/hum.2013.112. View

Sorenmo K, Krick E, Coughlin C, Overley B, Gregor T, Vonderheide R . CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One. 2011; 6(8):e24167. PMC: 3164165. DOI: 10.1371/journal.pone.0024167. View

Fanelli A, Licenziato L, Mazzone E, Divari S, Rinaldi A, Marino M . The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification. Sci Rep. 2024; 14(1):18687. PMC: 11319785. DOI: 10.1038/s41598-024-69716-6. View

10.

Purzycka K, Peters L, Desmas I, Davies O, Chang Y, Lara-Garcia A . Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases. Vet Comp Oncol. 2020; 18(4):656-663. DOI: 10.1111/vco.12589. View

11.

Wolfesberger B, Burger S, Kummer S, Walter I, Tichy A, Klinger S . Proliferation Activity in Canine Gastrointestinal Lymphoma. J Comp Pathol. 2021; 189:77-87. DOI: 10.1016/j.jcpa.2021.10.003. View

12.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

13.

Mu S, Ai L, Fan F, Qin Y, Sun C, Hu Y . Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. Cancer Cell Int. 2018; 18:119. PMC: 6103859. DOI: 10.1186/s12935-018-0609-9. View

14.

Jeglum K, Young K, Barnsley K, Whereat A . Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma. Cancer. 1988; 61(10):2042-50. DOI: 10.1002/1097-0142(19880515)61:10<2042::aid-cncr2820611019>3.0.co;2-q. View

15.

De Clercq E . Tanovea® for the treatment of lymphoma in dogs. Biochem Pharmacol. 2018; 154:265-269. DOI: 10.1016/j.bcp.2018.05.010. View

16.

Zandvliet M, Teske E, Schrickx J, Mol J . A longitudinal study of ABC transporter expression in canine multicentric lymphoma. Vet J. 2014; 205(2):263-71. DOI: 10.1016/j.tvjl.2014.11.002. View

17.

Cheson B . PET/CT in Lymphoma: Current Overview and Future Directions. Semin Nucl Med. 2017; 48(1):76-81. DOI: 10.1053/j.semnuclmed.2017.09.007. View

18.

Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas D, Vail D . Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma. Vet Radiol Ultrasound. 2009; 50(6):660-8. DOI: 10.1111/j.1740-8261.2009.01612.x. View

19.

Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo E, Avivi I . Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica. 2013; 99(1):125-30. PMC: 4007925. DOI: 10.3324/haematol.2013.088161. View

20.

Poggi A, Miniscalco B, Morello E, Gattino F, Delaude A, Ferrero Poschetto L . Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma. Vet Comp Oncol. 2016; 15(2):431-440. DOI: 10.1111/vco.12184. View